Canaccord Genuity Reiterates a 'Buy' on Vivus (VVUS); Addressing Teratogenecity Issue Next Step Towards Qnexa Approval
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Vivus (NASDAQ: VVUS), PT $15.
Canaccord analyst says, "Following a January meeting with the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Following a January meeting with the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
